| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | David Jackson | Q42889647 |
| P2093 | author name string | Mandvi Bharadwaj | |
| Eric J Gowans | |||
| Kathryn L Jones | |||
| P2860 | cites work | Costs of hepatitis C | Q23909277 |
| Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation | Q24290542 | ||
| Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein | Q24319002 | ||
| Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes | Q24673768 | ||
| Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees | Q27469342 | ||
| Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis | Q27469538 | ||
| Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. | Q27472875 | ||
| Comparative Analysis of Anti-Hepatitis C Virus Activity and Gene Expression Mediated by Alpha, Beta, and Gamma Interferons | Q27472908 | ||
| Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection | Q27472915 | ||
| Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease | Q27473001 | ||
| The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity | Q27473081 | ||
| Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles | Q27477687 | ||
| Cellular immune responses against hepatitis C virus: the evidence base 2002 | Q27480725 | ||
| Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses | Q27485419 | ||
| Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection | Q27485921 | ||
| Analysis of successful immune responses in persons infected with hepatitis C virus | Q27860698 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. | Q42995350 | ||
| Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. | Q42998720 | ||
| Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection | Q43001795 | ||
| Hepatitis C virus viremia following clinical resolution of acute hepatitis C. | Q43036071 | ||
| Expression of HCV structural proteins impairs IFN-mediated antiviral response | Q43039678 | ||
| Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. | Q43048494 | ||
| Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. | Q43049265 | ||
| The global burden of disease attributable to contaminated injections given in health care settings | Q43966617 | ||
| Detection of neutralizing antibodies to hepatitis C virus using a biliary cell infection model | Q44378451 | ||
| Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection | Q45737458 | ||
| Limited humoral immunity in hepatitis C virus infection | Q45752127 | ||
| Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity | Q45764886 | ||
| The first 1000 dendritic cell vaccinees. | Q50736412 | ||
| Cross-presentation: a general mechanism for CTL immunity and tolerance | Q57228022 | ||
| Acute hepatitis C | Q73427444 | ||
| Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy | Q73615496 | ||
| New insights into acute hepatitis C | Q73638751 | ||
| Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells | Q74310288 | ||
| Determinants of viral clearance and persistence during acute hepatitis C virus infection | Q28131757 | ||
| Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization | Q29615898 | ||
| Analysis of a successful immune response against hepatitis C virus | Q29619507 | ||
| The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies | Q29619723 | ||
| The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 | Q29620136 | ||
| HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help | Q29620766 | ||
| Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C | Q29620791 | ||
| Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection | Q29620795 | ||
| The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes | Q30004698 | ||
| Cell mediated immune response to the hepatitis C virus. | Q33791658 | ||
| Strategies and prospects for vaccination against the hepatitis C viruses | Q33791664 | ||
| Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection | Q33853655 | ||
| Noncytolytic control of viral infections by the innate and adaptive immune response | Q34178107 | ||
| Dendritic cells as a tool to induce anergic and regulatory T cells | Q34295082 | ||
| A new foreign policy: MHC class I molecules monitor the outside world | Q34398620 | ||
| Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant | Q34499902 | ||
| Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors | Q34787754 | ||
| Epidemiology of hepatitis C virus infection in Australia | Q35071449 | ||
| Kinetics of the immune response during HBV and HCV infection. | Q35164171 | ||
| Dendritic cells in immunity and tolerance-do they display opposite functions? | Q35181775 | ||
| Cross-genotype immunity to hepatitis C virus | Q35543288 | ||
| Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy | Q35635696 | ||
| Interleukin-12 inhibits hepatitis B virus replication in transgenic mice | Q35881471 | ||
| Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection | Q35890031 | ||
| Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity | Q36366130 | ||
| Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins | Q40555914 | ||
| Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus | Q40687696 | ||
| Dendritic cells: On the move from bench to bedside | Q40699456 | ||
| Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. | Q40896695 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Future approaches to treatment of chronic hepatitis B and hepatitis C infection | Q40909898 | ||
| Dendritic cells: unique leukocyte populations which control the primary immune response | Q41621775 | ||
| Dendritic cells as adjuvants for immune-mediated resistance to tumors | Q41649620 | ||
| Chronic hepatitis C virus infection established and maintained in chimpanzees independent of dendritic cell impairment | Q42980351 | ||
| Presence of functional dendritic cells in patients chronically infected with hepatitis C virus | Q42980525 | ||
| Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy | Q42985646 | ||
| Low stimulatory capacity of lymphoid dendritic cells expressing hepatitis C virus genes | Q42989574 | ||
| Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. | Q42989853 | ||
| Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals | Q42993342 | ||
| The interrelationship between hepatitis C virus and HLA. | Q42993371 | ||
| Comparison of cytotoxic T-lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals | Q42994713 | ||
| P433 | issue | 4 | |
| P921 | main subject | hepatitis C | Q154869 |
| dendritic cell | Q506253 | ||
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 283-290 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | Journal of Clinical Virology | Q15759726 |
| P1476 | title | Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus | |
| P478 | volume | 30 |
| Q34091925 | A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals |
| Q37082777 | CD4+ CD25+ regulatory T cells: a therapeutic target for liver diseases. |
| Q36307547 | Chronic hepatitis C virus infection and post-liver transplantation diabetes mellitus |
| Q34305417 | DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response |
| Q43034855 | Defining target antigens for CD25+ FOXP3 + IFN-gamma- regulatory T cells in chronic hepatitis C virus infection. |
| Q27481412 | Dendritic Cell Function during Chronic Hepatitis C Virus and Human Immunodeficiency Virus Type 1 Infection |
| Q36535789 | Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. |
| Q36198667 | Development of prophylactic and therapeutic vaccines against hepatitis C virus |
| Q53594310 | Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients. |
| Q26829202 | Hepatitis C virus infection and type 1 and type 2 diabetes mellitus |
| Q41785343 | Hepatitis C virus modulates human monocyte-derived dendritic cells |
| Q43035267 | Immunity and protection by adoptive transfer of dendritic cells transfected with hepatitis C NS3/4A mRNA. |
| Q24519072 | Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon |
| Q39297697 | Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells |
| Q35920469 | Long-term storage of DNA-free RNA for use in vaccine studies |
| Q79957776 | Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells |
| Q43040011 | Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile |
Search more.